Study of activation cross sections of double neutron capture reaction on 193Ir for the reactor production route of radiotherapeutic 195mPt

IF 3.6 4区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Nuclear medicine and biology Pub Date : 2024-05-18 DOI:10.1016/j.nucmedbio.2024.108928

Alexander S. Madumarov , Nikolay V. Aksenov , Gospodin A. Bozhikov , Andrey A. Astakhov , Yury V. Albin , Maksim V. Bulavin , Evgeny P. Shabalin , Sergey N. Dmitriev

{"title":"Study of activation cross sections of double neutron capture reaction on 193Ir for the reactor production route of radiotherapeutic 195mPt","authors":"Alexander S. Madumarov , Nikolay V. Aksenov , Gospodin A. Bozhikov , Andrey A. Astakhov , Yury V. Albin , Maksim V. Bulavin , Evgeny P. Shabalin , Sergey N. Dmitriev","doi":"10.1016/j.nucmedbio.2024.108928","DOIUrl":null,"url":null,"abstract":"<div>The radiotherapeutic 195mPt is among the most effective Auger electron emitters of the currently studied radionuclides that have a potential theranostic application in nuclear medicine. Production of 195mPt through double neuron capture of enriched 193Ir followed by β−-decay to the radioisotope of interest carried out at the research reactor IBR-2 is described. Because of the high radiation background, radiochemical purification procedure of 195mPt from bulk of iridium was needed to be developed and is detailed here as well. For the first time, cross section and resonance integral for the reaction 194Ir(n,γ)195mIr were determined. Resonance neutrons contribution was established to exceed that of thermal neutrons, and resonance integral for the reaction 194Ir(n,γ)195mIr is calculated to be 2900 b. Specific activity of 195mPt was estimated to reach a value of 38.7 GBq/(g Pt) at IBR-2 by the end of bombardment (EOB).</div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"134 ","pages":"Article 108928"},"PeriodicalIF":3.6000,"publicationDate":"2024-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear medicine and biology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0969805124000544","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

The radiotherapeutic ^195mPt is among the most effective Auger electron emitters of the currently studied radionuclides that have a potential theranostic application in nuclear medicine. Production of ^195mPt through double neuron capture of enriched ¹⁹³Ir followed by β⁻-decay to the radioisotope of interest carried out at the research reactor IBR-2 is described. Because of the high radiation background, radiochemical purification procedure of ^195mPt from bulk of iridium was needed to be developed and is detailed here as well. For the first time, cross section and resonance integral for the reaction ¹⁹⁴Ir(n,γ)^195mIr were determined. Resonance neutrons contribution was established to exceed that of thermal neutrons, and resonance integral for the reaction ¹⁹⁴Ir(n,γ)^195mIr is calculated to be 2900 b. Specific activity of ^195mPt was estimated to reach a value of 38.7 GBq/(g Pt) at IBR-2 by the end of bombardment (EOB).

Abstract Image

查看原文本刊更多论文

放射性治疗用 195mPt 反应堆生产路线中 193Ir 上双中子俘获反应的活化截面研究

195mPt 是目前研究的放射性核素中最有效的奥杰电子发射体之一，在核医学中具有潜在的治疗用途。195mPt 是在研究反应堆 IBR-2 中通过富集 193Ir 的双神经元俘获，然后通过β-衰变生成相关放射性同位素而产生的。由于辐射本底很高，需要开发从大量铱中提纯 195mPt 的放射化学纯化程序，本文也对此进行了详细介绍。首次测定了反应 194Ir(n,γ)195mIr 的截面和共振积分。共振中子的贡献超过了热中子的贡献，194Ir(n,γ)195mIr 反应的共振积分被计算为 2900 b。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nuclear medicine and biology 医学-核医学

CiteScore

6.00

自引率

9.70%

发文量

479

审稿时长

51 days

期刊介绍： Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized. These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field. Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.